About the Cell Signaling Program
Program Leader: Carol Lange, Ph.D.
Members of this program seek to define and understand the spectrum of altered signaling pathways and their components that contribute to cancer initiation, promotion, and disease progression. The goal is to facilitate the step-wide translation of this knowledge into novel strategies aimed at prevention, early detection, diagnostics and prognosis, and treatment of cancer. Programmatic focus includes the actions of cell surface receptors or nuclear receptors (i.e., steroid hormone receptors) and their ligands (the first messengers), intracellular second messengers, protein kinase cascades, and other signaling molecules that serve as modifiers of signal strength and duration, and the endpoints (substrates) of cell signaling pathways that regulate gene expression (transcription factors and their co-regulators, including DNA modifying enzymes).
- Nuclear and steroid hormone receptor actions
- Intracellular signaling and molecular targeted therapies
- Mechanisms of regulation of gene transcription
The Cell Signaling program holds monthly meetings in which single projects or multiple projects within related topic areas are discussed in an interactive roundtable format:
Khalil Ahmed, Ph.D.
Functional role of protein kinase CK2 in cancer cells, employing prostate cancer and head-and-neck cancer as experimental models.
Peter Argenta, M.D.
Early events in carcinogenesis and the treatment and prevention of ovarian cancer, with specific interest in using antiangiogenic agents in the management of metastatic tumors.
Vivian Bardwell, Ph.D.
The role of transcription factors in cancer and development.
Yue Chen, Ph.D.
Development and application of powerful proteomic technologies in combination with biochemistry, cell biology and computational analysis to understand the dynamic profiles of the PTM networks in various diseases, and reveal the correlation between cellular metabolism and diverse PTM pathways.
Scott Dehm, Ph.D.
Rose of the androgen receptor in prostate cancer development and progression
Gunda Georg, Ph.D.
Design, synthesis, and evaluation of synthetic and natural product-derived medicinal agents; drug discovery by HTS; new synthetic methods; combinatorial chemistry
Peter Gordon, M.D., Ph.D.
Development of approaches for overcoming bone marrow stromal cell mediated chemoresistance in AML and how factors secreted by cells within the leukemia microenvironment impact leukemia development and response to therapy
Timothy Hallstrom, Ph.D.
Cellular mechanisms controlling Rb/E2F induced apoptosis during normal proliferation and in cancer development
Daniel Harki, Ph.D
Design, synthesis and biophysical characterization of small molecules that influence cellular function
Ameeta Kelekar, Ph.D.
Pathways of cell survival and death with special emphasis on Bcl-2 family proteins as regulators of these pathways
Do-Hyung Kim, Ph.D.
Understanding the molecular networks that coordinate nutrient metabolism and cell growth
Badrinath Konedy, M.D., M.B.A.
Urologic oncology; urinary markers for bladder cancer; new diagnostics techniques for prostate cancer; development of novel agents including gene therapy for prostate cancer
Carol Lange, Ph.D.
Mechanisms of cancer progression involving signal transduction cross talk with steroid hormone receptors in breast, lung, and ovarian cancer models; role of MAPKs as major inputs to ligand-dependent and -independent progesterone receptor action and target gene selection in breast cancer; role of Brk/PTK6 actions upstream of ERK5 and p37 MAPK stress signalling pathways in breast tumor progression/ hypoxia
Cheuk T. Leung, Ph.D.
Mammary tumor initiation from normal tissue, and signaling of tumor dormancy and recurrence utilizing expertise in 3D organotypic models, molecular tool design for single-cell manipulation, 4D live imaging, and 3D screening platform development
Faqian Li, M.D., Ph.D.
Rose of the canonical Wnt pathway and epigenetic modifications in development and adult diseases; how signaling pathways interact with chromatic remodeling complex to modulate epigenome and gene expression
Thomas Neufeld, Ph.D.
Developmental mechanisms, genetic mechanisms, cell interactions, signal transduction, cell cycle regulation
Julie Ostrander, Ph.D.
Identification of biomarkers to identify pre-invasive breast cancer and response to chemoprevention
Vitaly Polunovsky, Ph.D.
The role of mRNA cap-dependent translation in breast cancer
David Potter, M.D., Ph.D.
Potential role for the HIV protease inhibitor, ritonavir, as a modulator of PI2-kinase/AKT signaling in breast cancer and the development of new therapeutic approaches to breast cancer based on its function. Also of interest are the mechanisms of calpain proteases in cell motility and cytoskeletal remodeling.
Teresa Rose-Hellekant, D.V.M., Ph.D.
Natural history of mammary cancer development; identification of molecular and cellular targets of tamoxifen chemoprevention; role of developmental genes in breast carcinogenesis; anticancer gene therapy and utility of mesenchymal stem cells; mouse modeling of cancer to study novel therapeutic and preventive drugs.
Deepali Sachdev, Ph.D.
Regulation of breast cancer biology by the insulin-like growth factors (IGFs) and the IGF-1 receptor
Ashok Saluja, Ph.D.
Role of heat shock proteins in the pathophysiology of the resistance of pancreatic cancer to apoptotic cell death.
Jeffrey Simon, Ph.D.
Animal development; control of gene expression; chromatin mechanisms; the role of EZH2 gene in mammary development; epigenetic alterations that cause cancer
Carston Wagner, PhD.
Rational design of novel anti-cancer therapeutics and nanotechnology based drug delivery systems by employing medicinal organic synthesis, immunology protein engineering, biochemistry and molecular modelling; Characterization of arylamine amine carcinogen metabolizing enzymes
Da-Qing Yang, Ph.D.
Signal transduction of ATM protein kianses in response to insulin and metformin in both diabetes and cancer; mechanisms of tumor suppressor gene function and cancer development, specifically regulation of p53 induction in response to DNA damage.
Douglas Yee, M.D.
Understanding the contribution of insulin-like growth factor (IFG) action to the breast cancer malignant phenotype; experimental new therapies for breast cancer.